-
公开(公告)号：US11274150B2
公开(公告)日：2022-03-15
申请号：US16683927
申请日：2019-11-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Natalie Bezman , Alan J. Korman , Shrikant Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger C. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
公开(公告)号：US20230174647A1
公开(公告)日：2023-06-08
申请号：US17845742
申请日：2022-06-21
Inventor： Xiao Min Schebye , Diana Yuhui Chen , Andrew Rankin , Xiaodi Deng , Joseph Toth , Linda Liang , Michelle Minhua Han , Christine Bee , Hong-An Truong , Mark J. Selby , Nils Lonberg , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova , Alan J. Korman
IPC: C07K16/28 , A61K47/68 , A61P35/00 , A61K39/395 , A61K45/06 , G01N33/563 , G01N33/577
CPC classification number: C07K16/2803 , A61K39/3955 , A61K45/06 , A61K47/6803 , A61P35/00 , C07K16/2827 , G01N33/563 , G01N33/577 , A61K2039/505
Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.
-
公开(公告)号：US20220204618A1
公开(公告)日：2022-06-30
申请号：US17670398
申请日：2022-02-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Natalie Bezman , Alan J. Korman , Shrikant Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger C. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
IPC: C07K16/28 , A61K39/395 , A61P35/00
Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
公开(公告)号：US11981734B2
公开(公告)日：2024-05-14
申请号：US17668807
申请日：2022-02-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Natalie Bezman , Alan J. Korman , Shrikant Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger C. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
IPC: C07K16/28 , A61K39/395 , A61K47/68 , A61P35/00 , C07K1/22 , C12N5/071 , C12N15/85 , C12P21/00 , G01N33/68 , A61K39/00
CPC classification number: C07K16/2803 , A61K39/3955 , A61K47/6849 , A61P35/00 , C07K1/22 , C12N5/0682 , C12N15/85 , C12P21/005 , G01N33/68 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C12N2510/02 , C12N2800/107
Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
公开(公告)号：US11591392B2
公开(公告)日：2023-02-28
申请号：US16697653
申请日：2019-11-27
Applicant: Bristol-Myers Squibb Company
Inventor： Xiao Min Schebye , Mark J. Selby , Michelle Minhua Han , Christine Bee , Andy X. Deng , Anan Chuntharapai , Brigitte Devaux , Huiming Li , Paul O. Sheppard , Alan J. Korman , Daniel F. Ardourel , Ekaterina Deyanova , Richard Huang , Guodong Chen , Michelle Kuhne , Hong-An Truong
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
-
Patent Agency Ranking
公开(公告)号：US10533052B2
公开(公告)日：2020-01-14
申请号：US16017489
申请日：2018-06-25
Applicant: Bristol-Myers Squibb Company
Inventor： Xiao Min Schebye , Mark J. Selby , Michelle Minhua Han , Christine Bee , Andy X. Deng , Anan Chuntharapai , Brigitte Devaux , Huiming Li , Paul O. Sheppard , Alan J. Korman , Daniel F. Ardourel , Ekaterina Deyanova , Richard Huang , Guodong Chen , Michelle Kuhne , Hong-An Truong
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
-
公开(公告)号：US12129297B2
公开(公告)日：2024-10-29
申请号：US16961545
申请日：2019-01-11
Applicant: Bristol-Myers Squibb Company
Inventor： Xiao Min Schebye , Mark J. Selby , Michelle Minhua Han , Christine Bee , Andy X. Deng , Anan Chuntharapai , Brigitte Devaux , Huiming Li , Paul O. Sheppard , Alan J. Korman , Daniel F. Ardourel , Ekaterina Deyanova , Richard Yu-Cheng Huang , Guodong Chen , Michelle Kuhne , Hong-An Truong
CPC classification number: C07K16/2803 , A61P35/00 , G01N33/6854 , A61K2039/507 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/74 , C07K2317/76 , C07K2317/92 , G01N2333/70503
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.
-
公开(公告)号：US20220195042A1
公开(公告)日：2022-06-23
申请号：US17668807
申请日：2022-02-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Natalie Bezman , Alan J. Korman , Shrikan Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger G. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
公开(公告)号：US10023634B2
公开(公告)日：2018-07-17
申请号：US15649380
申请日：2017-07-13
Applicant: Bristol-Myers Squibb Company
Inventor： Xiao Min Schebye , Mark J. Selby , Michelle Minhua Han , Christine Bee , Andy X. Deng , Anan Chuntharapai , Brigitte Devaux , Huiming Li , Paul O. Sheppard , Alan J. Korman , Daniel F. Ardourel , Ekaterina Deyanova , Richard Huang , Guodong Chen , Michelle Kuhne , Hong-An Troung
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
-
公开(公告)号：US12077584B2
公开(公告)日：2024-09-03
申请号：US17670398
申请日：2022-02-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Natalie Bezman , Alan J. Korman , Shrikant Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger C. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
IPC: C07K16/28 , A61K39/00 , A61K39/395 , A61K47/68 , A61P35/00 , C07K1/22 , C12N5/071 , C12N15/85 , C12P21/00 , G01N33/68
CPC classification number: C07K16/2803 , A61K39/3955 , A61K47/6849 , A61P35/00 , C07K1/22 , C12N5/0682 , C12N15/85 , C12P21/005 , G01N33/68 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C12N2510/02 , C12N2800/107
Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.023 seconds)
